Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

New England Journal of Medicine

Volumn 349, Issue 2, 2003, Pages 139-145

  Berger, Thomas ^a   Rubner, Paul ^a   Schautzer, Franz ^b   Egg, Robert ^a   Ulmer, Hanno ^a   Mayringer, Irmgard ^a   Dilitz, Erika ^a   Deisenhammer, Florian ^a   Reindl, Markus ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Villach Hospital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; MYELIN ASSOCIATED GLYCOPROTEIN; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEMYELINATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; SEROLOGY; WESTERN BLOTTING; BLOOD; BRAIN CORTEX; CHEMISTRY; EVALUATION; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RECURRENT DISEASE;

ADOLESCENT; ADULT; AUTOANTIBODIES; CEREBRAL CORTEX; CEREBROSPINAL FLUID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; RECURRENCE;

EID: 0038790058     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022328     Document Type: Article

References (36)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
2. O'Riordan JI, Thompson AJ, Kingsley DPE, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998;121:495-503.
3. Jacobs ID, Kaba SE, Miller CM, Priore RL, Brownscheidle CM. Correlations of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997;41:392-8.
4. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346:158-64.
5. McAlpine D. The benign form of multiple sclerosis: a study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961;84:186-203.
6. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112:1419-28.
7. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34.
8. Achiron A, Barak Y. Multiple sclerosis from probable to definite diagnosis: a 7-year prospective study. Arch Neurol 2000;57: 974-9.
9. Galboiz Y, Miller A. Immunological indicators of disease activity and prognosis in multiple sclerosis. Curr Opin Neurol 2002; 15:233-7.
10. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47-53.
11. Rudick RA, Cohen JA, Weinstock-Guttmann B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997;337:1604-11.
12. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343: 898-904.
13. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82.
14. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.
15. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of autoantigen. Nature 1992;358:155-7.
16. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95.
17. McFarland HI, Lobito AA, Johnson MM, et al. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J Immunol 1999; 162:2384-90.
18. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000;123:508-18.
19. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 1996; 183:1777-88.
20. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994;117:1311-22.
21. Luccinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis. Brain Pathol 1996;6:259-74.
22. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody-and complement-mediated demyelination. Ann Neurol 1998;43:465-71.
23. Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999;122:2047-56.
24. Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 2001;7:285-9.
25. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J Neurochem 1989;52:296-304.
26. Kerlero de Rosbo N, Honegger P, Lassmann H, Matthieu JM. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 1990; 55:583-7.
27. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130:443-54.
28. Stefferl A, Brehm U, Storch M, et al. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the "resistant" Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. J Immunol 1999;163:40-9.
29. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-5.
30. Adelmann M, Wood J, Benzel I, et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995;63:17-27.
31. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 38:1822-5.
32. Matthews B. Differential diagnosis of multiple sclerosis and related disorders. In: Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H, eds. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingstone, 1998:223-50.
33. Link H, Tibblieng G. Principles of albumin and IgG analysis in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977;37:397-401.
34. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
35. Brück W, Neubert K, Berger T, Weber JR. Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination - possible markers for an antibody-mediated process. Mult Scler 2001;7:173-7.
36. von Büdingen HC, Hauser SL, Fuhrmann A, Nabavi CB, Lee JI, Genain CP. Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl Acad Sci U S A 2002;99:8207-12.